In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever
Issued Date
2024-01-01
Resource Type
eISSN
21638306
Scopus ID
2-s2.0-85204647900
Journal Title
CPT: Pharmacometrics and Systems Pharmacology
Rights Holder(s)
SCOPUS
Bibliographic Citation
CPT: Pharmacometrics and Systems Pharmacology (2024)
Suggested Citation
Ding J., Mairiang D., Prayongkul D., Puttikhunt C., Noisakran S., Kaewjiw N., Songjaeng A., Prommool T., Tangthawornchaikul N., Angkasekwinai N., Suputtamongkol Y., Lapphra K., Chokephaibulkit K., White N.J., Avirutnan P., Tarning J. In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever. CPT: Pharmacometrics and Systems Pharmacology (2024). doi:10.1002/psp4.13233 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101420
Title
In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever
Corresponding Author(s)
Other Contributor(s)
Abstract
The increased incidence of dengue poses a substantially global public health challenge. There are no approved antiviral drugs to treat dengue infections. Ivermectin, an old anti-parasitic drug, had no effect on dengue viremia, but reduced the dengue non-structural protein 1 (NS1) in a clinical trial. This is potentially important, as NS1 may play a causal role in the pathogenesis of severe dengue. This study established an in-host model to characterize the plasma kinetics of dengue virus and NS1 with host immunity and evaluated the effects of ivermectin, using a population pharmacokinetic–pharmacodynamic (PK–PD) modeling approach, based on two studies in acute dengue fever: a placebo-controlled ivermectin study in 250 adult patients and an ivermectin PK–PD study in 24 pediatric patients. The proposed model described adequately the observed ivermectin pharmacokinetics, viral load, and NS1 data. Bodyweight was a significant covariate on ivermectin pharmacokinetics. We found that ivermectin reduced NS1 with an EC50 of 67.5 μg/mL. In silico simulations suggested that ivermectin should be dosed within 48 h after fever onset, and that a daily dosage of 800 μg/kg could achieve substantial NS1 reduction. The in-host dengue model is useful to assess the drug effect in antiviral drug development for dengue fever.